In a recent article published in the Journal of Oncology Practice, oncologists Ray Drasga and Lawrence Einhorn called on their colleagues to support “an improved Medicare for all” program.
Studies assessing the merits of cancer screening tend to get a lot of play in the news media. It seems every six months or so a new study makes a big splash.
A meeting of the FDA Oncologic Drugs Advisory Committee has become a rare occurrence.
AVEO Oncology and Astellas Pharma Inc. discontinued a phase II study of tivozanib in locally recurrent or metastatic triple-negative breast cancer due to insufficient enrollment.
CVS Caremark plans to stop selling cigarettes and other tobacco products at more than 7,600 CVS/pharmacy stores by Oct. 1.
Responding to questions from The Cancer Letter, Jim Newman, director of external communications at MD Anderson, confirmed that the presentation obtained by The Cancer Letter was prepared under a contract by McKinsey & Company.
You might think of this as an event isolated to Columbus or central Ohio:
FDA notified Cell Therapeutics Inc. that the partial clinical hold on tosedostat (IND 075503) has been removed and all studies underway may continue.
The American Cancer Society and Stand Up To Cancer announced a collaboration to fund translational research and advocacy programs.
In his state of the union address to Congress Jan. 28, President Barack Obama called for reversing the cuts made to basic research in the federal budget.
